Compare OVLY & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OVLY | VYGR |
|---|---|---|
| Founded | 1990 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.2M | 226.8M |
| IPO Year | N/A | 2015 |
| Metric | OVLY | VYGR |
|---|---|---|
| Price | $31.69 | $3.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 12.7K | ★ 516.9K |
| Earning Date | 01-23-2026 | 11-10-2025 |
| Dividend Yield | ★ 1.94% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.84 | N/A |
| Revenue | ★ $79,783,000.00 | $31,316,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $71.78 |
| P/E Ratio | $10.89 | ★ N/A |
| Revenue Growth | ★ 2.98 | N/A |
| 52 Week Low | $22.70 | $2.65 |
| 52 Week High | $31.45 | $5.96 |
| Indicator | OVLY | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 66.81 | 39.01 |
| Support Level | $30.03 | $3.81 |
| Resistance Level | $30.72 | $4.24 |
| Average True Range (ATR) | 0.72 | 0.21 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 82.49 | 6.73 |
Oak Valley Bancorp is a bank holding company that operates through Oak Valley Community Bank (the Bank). The Bank offers a complement of business checking and savings accounts for its business customers. The Bank also offers commercial and real estate loans, as well as lines of credit. In addition, the bank provides other services for both individuals and businesses including online banking, remote deposit capture, mobile banking, merchant services, night depository, extended hours, wire transfer of funds, note collection, and automated teller machines in a national network. Its primary source of revenue is net interest income.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.